MedTrace Logo

Neural Progenitor Cell and Paracrine Factors to Treat Hypoxic Ischemic Encephalopathy

NCT02854579 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2016-08-03

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy and safety of allogenic neural progenitor cell and paracrine factors of human mesenchymal stem cells for patients with moderate/severe Hypoxic-Ischemic Encephalopathy

Conditions

  • Hypoxic-Ischemic Encephalopathy

Interventions

BIOLOGICAL

neural progenitor cell

Neural progenitor cells are derived from the same aborted human fetal forebrain.

BIOLOGICAL

Paracrine factors

The factors obtained from cultured human mesenchymal stem cells were concentrated 50 times

BIOLOGICAL

progenitor cell and paracrine factors

Neural progenitor cells will be received after paracrine factors therapy

Sponsors & Collaborators

  • Bethune International Peace Hospital

    collaborator OTHER

  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

    collaborator OTHER

  • Hunan Children's Hospital

    collaborator OTHER_GOV

  • Shangluo Central Hospital

    collaborator OTHER

  • 252 Military Hospital

    collaborator UNKNOWN

  • Navy General Hospital, Beijing

    lead OTHER

Principal Investigators

  • Zuo Luan, MD · Navy General Hosiptal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Day
Max Age
14 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2017-07-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02854579 on ClinicalTrials.gov